Pain is a prevalent condition that can have a serious impact upon the socioeconomic function of a population.
Introduction 39 40
Pain is associated with a number of well-documented disease states; including for example rheumatoid 41 arthritis, malignant disease and conditions of idiopathic origin [1] . Consequently, pain is a prevailing complaint 42 that presents worldwide and within the United Kingdom it is estimated that thousands of people experience 
50
The lung serves as an effective portal for drug delivery to the body due to the large surface area for 51 absorption, the highly vascularised nature of the organ plus the thin, moist air-blood barrier [5] . The delivery 52 of particulate material to the respiratory tract is an inefficient process, with typically only 20% of the emitted 53 dose reaching the lung and contacting pulmonary surfactant [6] . This notable inefficiency may be ascribed to a 54 number of factors, including for example material cohesion / adhesion, particle size distribution along with 55 particle morphology [7] . Thus, in order to maximise the availability of drug substance for therapeutic benefit, 56 a formulation should exhibit the best possible combination of physicochemical characteristics (e.g. particle size 57 (optimal range between 1µm -5μm), shape, crystal form, solubility, bioavailability and stability). Of 58 significance to the work presented herein, it is the morphology of the respirable material (and hence exposed 59 chemical functionalities) that will principally govern the interaction profile between an active pharmaceutical 60 ingredient (API) and pulmonary surfactant [8] .
61 62 63 64 3 | P a g e On delivery to the (deep) lung, an aerosolised formulation will initially interact with pulmonary surfactant 65 [9 & 10] . This material is a complex biological mixture that lines the inner surface of the lung (i.e. the alveolar 66 space) and reduces the surface tension term to maintain airway patency [11] . During the process of tidal 67 breathing, variation in pulmonary surfactant physical characteristics occurs [12] , which can in turn influence 68 the processes of drug particle dissolution and subsequent absorption [13] . and control glycine crystal development [20] . Various operating parameters were noted to influence resultant 96 crystal habits; including for instance the pH of the subphase and monolayer surface pressure. Flexibility in 97 operating conditions can thus afford the formulator with scope to achieve control over crystalline properties 98 (e.g. exposed surface chemistries).
99
Although Langmuir monolayers hold potential to inform understanding surrounding API nucleation and crystal 100 growth within simulated pulmonary environments, several drawbacks (e.g. low crystal yield plus large particle 101 size distribution) preclude use for industrial scale-up and patient end-use. Therefore, it is necessary to 102 investigate alternative routes of crystallisation, such as antisolvent crystallisation with biologically relevant 103 additives, to achieve controlled crystal growth and support chemical complementarity with appropriate yields.
104
The strategy involves the addition of a second solvent (i.e. ethanol) to a supersaturated, drug-containing 105 solution to reduce drug solubility and initiate crystallisation [21] . Typically, this approach is rapid and 106 generates a large number of micron-sized drug particles that are suitable for delivery to the (deep) lung. This 107 particular methodology was applied by Xie and co-workers in 2010, whereby a range of additives were used to 108 achieve control over drug crystal size and form [22] 
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With respect to the material produced via antisolvent crystallisation, the particle size was significantly smaller. 
296
The crystallisation environment dictated gross particle morphology. 
X-ray Diffraction Analysis 327 328
The crystalline material recovered from each system under investigation was subject to XRD examination; 329 representative traces are illustrated in Figure 5 . 
367
The XRD data acquired from the mixed monolayer system at 5mN/m demonstrates dominance in the (100)
368
reflection. This result may be ascribed to the conditions under which the crystals were allowed to grow (i.e. an The XRD analysis for aspirin crystals recovered from the antisolvent crystallisation system with DPPC 5% as a 380 lung-specific additive indicate that a number of reflections present (i.e. a random array of peaks are evident).
381
Here, the (100) facet presents at 30%, the (200) face at 100%, (300) plane at 51% and (400) 
472
With commercially available respirable formulations in mind, there is no guarantee that such preferred 473 external chemistries between a drug particle and pulmonary surfactant will come into contact, in effect the 474 association between each species is essentially uncontrolled. increased the resultant particle size decreased, which also held true when the temperature of the system was 495 increased. Importantly, the group noted that smaller drug-containing particles were generated with rapid 496 introduction of the antisolvent (10ml/min) compared to larger particles with slower introduction (1.4ml/min); 497 the average particle size range was reported to be 62.1µm -112.3µm, respectively. Moreover, the rate of 498 antisolvent addition did not influence the crystal habit; hence, exposed chemical moieties remained constant.
499
Thus, the authors demonstrate that antisolvent crystallisation can provide a route to manufacture drug-500 containing particulates within a narrow particle size range at the 10's of micron scale. 
